Strengthening the Ultra-Fast Gene Quantification Instrument Business through the Acquisition of Jitas

「Compared with the existing GeneSoC Influenza Virus A/B Detection Kit, this product improves detection sensitivity and shortens measurement time.」

「As part of its diagnostic-business initiatives, the company is focusing on expanding sales of in vitro diagnostics, including SARS coronavirus nucleic acid detection kits and influenza-virus nucleic acid kits, and is promoting the development of GeneSoC-specific research-use reagents and in vitro diagnostics, including the launch of a Bordetella pertussis detection kit in June 2024. In October 2024, it also launched the genetic analysis system GeneSoC mini 2, an improved version of the existing GeneSoC mini.」

「In the fiscal year ended March 2024, the company obtained marketing approval for the manufacture and sale of the GeneSoC Bordetella pertussis Detection Kit, a Bordetella pertussis nucleic acid kit, and launched the research-use reagents GeneSoC Treponema pallidum Detection Kit (for research use) and GeneSoC HIV-1 Detection Kit (for research use).」

「The company also obtained marketing approval for the manufacture and sale of a Bordetella pertussis nucleic acid kit as an in vitro diagnostic product. It will continue to promote the development and sale of GeneSoC-specific research-use reagents and in vitro diagnostic products in areas including respiratory and sexually transmitted diseases, and will actively work to contribute to the prevention, diagnosis and treatment of infectious diseases through these products.」

「As part of its initiatives in the diagnostics business, the company focused on expanding sales of newly launched in vitro diagnostic products in the fiscal year ending March 2023, comprising a novel coronavirus nucleic acid detection kit and an influenza virus nucleic acid kit. It will continue to seek to make a further contribution to shortening PCR testing times and establishing rapid genetic detection methods for infectious diseases, including COVID-19.」

「The company also launched GeneSoC miniR, an ultrafast real-time PCR instrument developed for the life sciences and scientific instrument markets, in March 2023.」

「The company also obtained manufacturing and marketing approval in August of the same year for the GeneSoC Influenza Virus A/B Detection Kit as an in vitro diagnostic, and launched it in November of the same year.」

「The company launched the GeneSoC SARS-CoV-2 N2 Detection Kit, a nucleic acid detection kit for the novel coronavirus, in April 2022. It will continue to seek to make a further contribution to strengthening testing capacity, including shortening the time required for PCR testing in the diagnosis of COVID-19.」

「As part of its diagnostic-business initiatives, the company launched a PCR pretreatment kit for detecting COVID-19 in July 2021 and the genetic analysis system GeneSoC mini in November of the same year.」

「As part of its initiatives in the diagnostics business, the company worked to promote the adoption of GeneSoC and ensure a stable supply of reagents, and launched a PCR sample-preparation kit for novel coronavirus detection in July 2021」

「Kyorin Pharmaceutical Co., Ltd. launched a PCR sample-preparation kit for novel coronavirus detection for use with the microfluidic genetic quantification instrument GeneSoC® in July 2021.」

「In the diagnostics business, the company worked to promote the adoption of the microfluidic genetic quantification instrument GeneSoC® and SARS‐CoV‐2 GeneSoC ER Kyorin, a novel coronavirus detection reagent launched in April 2020.」

「As part of its initiatives in the diagnostics business, Kyorin Pharmaceutical Co., Ltd. aims to launch a dedicated automated sample-preparation device and the point-of-care testing model GeneSoC® mini, alongside the wider adoption of the microfluidic genetic quantification instrument GeneSoC® and SARS‐CoV‐2 GeneSoC ER Kyorin, a novel coronavirus detection reagent launched in April 2020.」

「As part of its initiatives in the diagnostics business, Kyorin Pharmaceutical Co., Ltd. launched SARS‐CoV‐2 GeneSoC ER Kyorin, a reagent for detecting the novel coronavirus for use with the microfluidic genetic quantification instrument GeneSoC®, in April 2020.」

「The company also newly entered the diagnostics business, advancing the development of in vitro diagnostic products to identify the causative bacteria and viruses of infectious diseases, and launched GeneSoC as a research-use instrument.」

「Kyorin Pharmaceutical Co., Ltd. acquired all shares of ㈱ジェイタス in July 2017 and completed the absorption-type merger of the company in September of the same year.」

「Acquired all shares of ㈱ジェイタス on 3 July 2017 and completed the absorption-type merger on 30 September of the same year.」

「KYORIN Pharmaceutical Co.,Ltd. entered into an agreement on 23 June 2017 to acquire all shares of Jitas Co., Ltd. Jitas was established as a venture originating from the National Institute of Advanced Industrial Science and Technology to commercialize technology developed by the institute. It developed GeneSoC, an ultra-fast gene quantification instrument that uses proprietary improvements to PCR technology to identify bacteria, viruses and other pathogens in a short period. The Group expects to strengthen its infectious disease treatment and diagnostics businesses by utilizing this technology. The acquisition was completed on 3 July 2017.」